Related Experiment Videos
[Perspectives on the oncologist pharmacopoeia]
Amélie Lansiaux1, Christian Bailly
1Laboratoire de pharmacologie antitumorale du Centre Oscar-Lambret et Unité 524 Inserm, 1, place de Verdun, 59045 Lille France.
Bulletin Du Cancer
|March 1, 2003
Summary
This review surveys new cancer drug targets and their clinical advances. It covers novel therapies like proteasome inhibitors and tyrosine kinase receptor inhibitors for 21st-century oncology.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- The 21st century demands novel therapeutic agents to combat cancer.
- Existing treatments require complementary strategies to improve patient outcomes.
Purpose of the Study:
- To review emerging drug candidates and their molecular targets.
- To survey the clinical progress of these novel therapeutic agents.
Main Methods:
- Literature review of preclinical and clinical data.
- Identification of drug code names and their associated molecular targets.
- Analysis of clinical advances in drug development.
Main Results:
- Identified numerous drug candidates (e.g., MGI114, ET743, STI571) targeting key cellular components.
- Highlighted targets including DNA grooves, ribonucleotide reductase, topoisomerases, tubulin, proteasome, and various protein kinases.
- Summarized clinical progress for drugs targeting protein kinase C, bcr-abl, and EGF/VEGF tyrosine kinase receptors.
Conclusions:
- New drugs targeting specific molecular pathways represent a significant advancement in cancer therapy.
- These novel agents are poised to enhance the oncologist's therapeutic arsenal.
- Continued research and clinical trials are crucial for realizing the full potential of these targeted therapies.